Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EDIT · as of Sep 30, 2025
Ownership Breakdown
207
Institutional Holders
▲ 8 vs Q2
$149.51M
Total Inst. Value
▲ $58.54M vs Q2
97.90M
Shares Outstanding
freeFloat 99.83%
43.11M
13F Shares Held
▲ 1.77M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EDIT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 8.02M | 9.50% | 9.50% | $27.83B | Nov 12, 2025 | ▲ 1.20M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 6.97M | 8.25% | 8.25% | $24.17B | Nov 7, 2025 | ▼ 193.9K |
NUVEEN, LLC biological products, (no diagnostic substances) | 2.09M | 2.48% | 2.48% | $7.26B | Nov 12, 2025 | ▲ 1.14M |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.04M | 2.42% | 2.42% | $7.08B | Nov 12, 2025 | ▲ 75.9K |
STATE STREET CORP biological products, (no diagnostic substances) | 1.93M | 2.28% | 2.28% | $6.68B | Nov 14, 2025 | ▲ 78.2K |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 1.58M | 1.88% | 1.88% | $5.50B | Nov 14, 2025 | ▲ 614.2K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 1.28M | 1.51% | 1.51% | $4.43B | Nov 13, 2025 | ▲ 389.0K |
TWO SIGMA ADVISERS, LP biological products, (no diagnostic substances) | 1.21M | 1.43% | 1.43% | $4.18B | Nov 14, 2025 | ▲ 264.4K |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.09M | 1.29% | 1.29% | $3.78B | May 27, 2026 | ▼ 332.8K |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 1.02M | 1.21% | 1.21% | $3.55B | Feb 3, 2026 | ▼ 55.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
21
Increased
+5.46M shares6
New Positions
first time holders23
Decreased
−3.92M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.54M
+5.46M / −3.92M
Net new holders
+4
6 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EDIT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
3
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Parison Amy SVP, Chief Financial Officer | Jun 3, 2026 | Sale | 464 | $2.70 | $1.3K | 15.0K | Form 4 ↗ |
O'Neill Gilmore Neil CEO | Jun 3, 2026 | Sale | 15,380 | $2.70 | $41.5K | 248.3K | Form 4 ↗ |
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Jun 3, 2026 | Sale | 731 | $2.70 | $2.0K | 67.3K | Form 4 ↗ |
O'Neill Gilmore Neil CEO | Mar 12, 2026 | Award | 1,015,200 | $2.54 | $2.58M | 1.02M | Form 4 ↗ |
Parison Amy SVP, Chief Financial Officer | Mar 12, 2026 | Award | 292,856 | $2.54 | $743.9K | 292.9K | Form 4 ↗ |
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Mar 12, 2026 | Award | 292,856 | $2.54 | $743.9K | 292.9K | Form 4 ↗ |
O'Neill Gilmore Neil CEO | Mar 3, 2026 | Sale | 5,394 | $2.02 | $10.9K | 263.7K | Form 4 ↗ |
Parison Amy SVP, Chief Financial Officer | Mar 3, 2026 | Sale | 474 | $2.02 | $957.48 | 15.4K | Form 4 ↗ |
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Mar 3, 2026 | Sale | 749 | $2.02 | $1.5K | 68.0K | Form 4 ↗ |
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Dec 3, 2025 | Sale | 713 | $2.15 | $1.5K | 68.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Editas Medicine, Inc. (EDIT) is primarily owned by institutional investors, who hold approximately 44.0% of total shares outstanding. Company insiders own approximately 0.17%, while retail and public investors account for the remaining 55.80%.
The largest institutional shareholder of Editas Medicine, Inc. is BLACKROCK, INC., holding approximately 8.02 million shares — equal to 9.50% of outstanding shares — as of September 30, 2025.
A total of 207 institutional investors currently hold EDIT stock, with a combined institutional value of approximately $149,509,963 as of the most recent 13F filing period.
Frequently asked questions
EDIT ownershipEditas Medicine, Inc. (EDIT) is primarily owned by institutional investors, who hold approximately 44.0% of shares. The largest shareholder is BLACKROCK, INC. with a 9.50% stake. Company insiders hold 0.17%. Data sourced from SEC Form 13F as of September 30, 2025.